Study on the synthesis of Exemestane

Please use this identifier to cite or link to this item: https://dspace.ctu.edu.vn/jspui/handle/123456789/21866

Full metadata record

DC Field	Value	Language
dc.contributor.author	Cao, Duc Tuan	-
dc.contributor.author	Vu, Thi Kim Loan	-
dc.contributor.author	Trinh, Hien Trung	-
dc.contributor.author	Nguyen, Van Hung	-
dc.contributor.author	Pham, Van Thuc	-
dc.date.accessioned	2020-02-26T09:11:03Z	-
dc.date.available	2020-02-26T09:11:03Z	-
dc.date.issued	2018	-
dc.identifier.issn	2525-2321	-
dc.identifier.uri	http://dspace.ctu.edu.vn/jspui/handle/123456789/21866	-
dc.description.abstract	Exemestane, a 3rᵈ-generation aromatase inhibitor, has been approved by FDA for the treatment of advanced breast cancer in postmenopausal women since 1995 and its patent was expired in 2015. Since the approval, Exemestane has been widely used in breast cancer patients and is shown to have good clinical effects. There are several published synthesis methods of Exemestane but there is not any such report in Viet Nam. Herein, we describe the two-step method for the synthesis of Exemestane from the commercial available compound, androst-4-ene-3,17-dione. The total yield of the synthesized Exemestane is 27.12 %. The structure of Exemestane and intermediate products were elucidated by MS and NMR spectroscopies.	vi_VN
dc.language.iso	en	vi_VN
dc.relation.ispartofseries	Vietnam Journal of Chemistry;No 56(06) .- Page.700-703	-
dc.subject	Exemestane	vi_VN
dc.subject	Steroid	vi_VN
dc.subject	Breast cancer	vi_VN
dc.subject	Androst-4-ene-3	vi_VN
dc.subject	17-dione	vi_VN
dc.title	Study on the synthesis of Exemestane	vi_VN
dc.type	Article	vi_VN
Appears in Collections:	Vietnam Journal of Chemistry

Files in This Item:

File	Description	Size	Format
_file_ Restricted Access		2.63 MB	Adobe PDF
Your IP: 3.15.192.89

LRC Digital repo